MarketList of EORTC trials
Company Profile

List of EORTC trials

This page is a list of EORTC clinical trials sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).

Breast cancer
• EORTC 10085 – characterization of male breast cancer • EORTC 10863 – continuous tamoxifen versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate • EORTC 10951 – exemestane versus tamoxifen Older studiesNafoxidine versus ethinylestradiolLevodopa versus nafoxidine ==Prostate cancer==
Prostate cancer
The following prostate cancer trials have been conducted, among others: • EORTC 30761 – cyproterone acetate 250 mg/day versus medroxyprogesterone acetate 200 mg/day versus diethylstilbestrol 3 mg/day • EORTC 30762 – estramustine phosphate 280 mg/day (560 mg/day initially) versus diethylstilbestrol 3 mg/day • EORTC 30843 – orchiectomy versus buserelin versus buserelin plus cyproterone acetate (150 mg/day) • EORTC 30853 – orchiectomy versus goserelin plus flutamide (750 mg/day) • EORTC 30892 – flutamide monotherapy (750 mg/day) versus cyproterone acetate (300 mg/day) • EORTC 30903 – prednisone versus flutamide • EORTC 30958 – intermittent combined androgen blockade == References ==
tickerdossier.comtickerdossier.substack.com